Allergan Press Releases

DUBLIN, Oct. 19, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company with a nearly 70-year heritage in ophthalmology, will present new data at the Annual Meeting of the American College of Ophthalmology (AAO) to be held in Chicago, Illinois. The Retina Subspecialty Day (October 26-27) will feature two late-breaker presentations on the company's ophthalmology pipeline, including new findings for abicipar in patients with neovascular age-related macular degeneration (nAMD) and brimonidine drug delivery system (DDS) in patients with geographic atrophy secondary to AMD. Additional company-sponsored data will also be presented during the AAO poster sessions.

DUBLIN, Oct. 17, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. The first study (UBR-MD-04) evaluated the long-term safety and tolerability of ubrogepant (50 mg and 100 mg) compared to usual care for the acute treatment of migraine in adults for one year.The second study (3110-105-002) evaluated the hepatic safety and tolerability of ubrogepant 100 mg compared to placebo in healthy study participants over eight weeks. 

DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October 11-14. The meeting will be held at the JW Marriott Desert Ridge Resort & Spa and the scheduled times (noted in local Mountain Time) of the presentations, titles and authors are as follows:

DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG), from October 5-10, 2018 in Philadelphia, PA. "Allergan is working to change treatment paradigms across gastroenterology with our Open Science research and development model," said David Nicholson, Chief Research and Development Officer, Allergan. "We are committed to uncovering the full potential of our approved medicines as well as collaborating with leading researchers to advance the investigational therapies in our pipeline. We look forward to showcasing our latest research to gastroenterologists at this important annual meeting."

DUBLIN, Oct. 5, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn's disease) and EXPEDITION (ulcerative colitis), will evaluate the safety and efficacy of brazikumab and will investigate the role of biomarkers in determining a predictive response of brazikumab in patients with IBD. They are the first active comparator studies of an IL-23 inhibitor therapy in IBD to evaluate biomarkers as potential predictors of treatment response and the first randomized comparison of an IL-23 inhibitor versus HUMIRA^® (adalimumab) in Crohn's disease and ENTYVIO^® (vedolizumab) in ulcerative colitis.

DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting^® treatment received FDA clearance to treat the submandibular area. In addition, the FDA clearance was expanded to include patients with a BMI of up to 46.2 when treating the submental and submandibular areas. This recent clearance makes CoolSculpting^® the first and only nonsurgical fat reduction treatment to contour the area below the jawline and improve the appearance of lax tissue in conjunction with submental fat treatments.

DUBLIN, Oct. 3, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today the launch of a new JUVÉDERM^® advertising campaign created to empower the next generation of consumers to "JUVÉDERM^® IT." JUVÉDERM^® IT marks the first new advertising campaign in three years for the world's #1 selling dermal filler collection¹ and was designed to further Allergan's goal of making the JUVÉDERM^® Collection of Fillers a first choice and household name for consumers.

DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.S. financial markets. Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, October 30, 2018 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 2759968.

DUBLIN, Sept. 28, 2018 /PRNewswire/ -- In celebration of breast cancer awareness month, Allergan plc (NYSE: AGN) announced today The Allergan Foundation's continuing commitment to breast health, awareness, restoration, and research through a $2,000,000 pledge to be paid over the next three years to select nonprofit organizations.

DUBLIN, Sept. 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for VRAYLAR^® (cariprazine), seeking to expand the indication to include the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults in the current product label.